The first FDA-cleared device that supports concurrent reading, allowing for faster reading with proven, superior, automatic nodule detection.
Our five FDA-cleared applications are designed to improve reading efficiency and accuracy across the hospital enterprise without additional equipment, procedures or radiation dose.
Riverain’s deep learning AI technology is FDA cleared, field tested, and clinically proven to provide real results in radiology.
Riverain Technologies advanced AI imaging software is in use by leading healthcare organizations around the world.
Peer reviews, reference accounts, and independent studies confirm that ClearRead technology is positively impacting the field of radiology.
Managing your lung program can seem daunting, whether you’re getting going, growing, or managing workflow. We’ve curated resources for you.
Riverain Technologies is on a mission to revolutionize radiology by eliminating delayed cardio-thoracic disease diagnoses. Using unique suppression technology, the ClearRead imaging interpretation solutions with Clear Visual Intelligence™ (CVI) create an unimpaired view within the existing workflow so radiologists can focus on what matters to detect, precisely characterize, and report findings.
Riverain ClearRead solutions significantly improve a clinician’s ability to accurately and efficiently detect disease in thoracic (chest) CT and XR images and more successfully address the challenges of early detection of lung disease. Powered by machine learning and advanced modeling, the patented, FDA-cleared ClearRead software tools are deployed in the clinic or the cloud and are powered by the most advanced AI methods available to the medical imaging market. While the benefit for patients can be life changing, the advantages for radiologists are equally substantial. Battling growing workloads and less time, ClearRead solutions allow clinicians to complete more reads faster – saving valuable time without sacrificing performance.
To eliminate delayed cardio-thoracic disease diagnoses.
To be recognized as a transformative leader in the thoracic sciences.
Dr. Jared Christensen is vice chair of strategy of the Duke University Department of Radiology and director of the Duke Lung Cancer Screening Program. He currently serves as chair of the American College of Radiology Lung-RADS Committee. Dr. Christensen’s professional interests in AI focus on finding solutions that decrease variability, increase efficiency, and improve patient outcomes.
Dr. Jonathan Chung, Divisional Chief of Cardiothoracic Imaging, University of California San Diego Medical Center, specializes in cardiopulmonary imaging. He analyzes and interprets chest radiographs and CT scans for thoracic diseases. He also has expertise in interstitial lung disease, occupational lung disease, nontuberculous mycobacterial pneumonia, and diseases of the large and small airways. He has authored over 190 peer-reviewed articles that have been published in scientific journals, co-authored numerous book chapters and seven books that focus on chest diagnostics.
Dr. Charles White has been on the Riverain advisory board since 2013, and is Professor of Radiology and Medicine at the University of Maryland Medical Center. Dr. White has a special interest in the diagnosis and staging of lung cancer and cardiac CT imaging. Dr. White was named one of Baltimore Magazine’s 2010 “Top Docs” for General Diagnostic Radiology.
Steve Worrell
Steve became CEO of Riverain Technologies in 2013 after joining Riverain as Vice President of Research in 2007. Prior to joining Riverain Technologies, he was a principal developer of iCAD’s SecondLook mammography computer aided detection (CAD) system. His primary focus was the development of iCAD’s microcalcification detection system. His earlier career included development of model based vision systems for military applications using synthetic aperture radar. Since joining Riverain Technologies his focus has been on developing, marketing, and commercializing Riverain’s X-ray and CT product lines.
Jason Knapp
Jason leads the development and research teams in the construction of advanced AI applications for medical imaging, bringing 20 years of industrial machine-learning experience. Over the past decade, he has developed the methodology used by Riverain for creating AI applications. This includes ensuring the robustness to changes in imaging devices and the use of synthetic disease to train large neural networks. He is the inventor of Riverain’s approaches to bone suppression in chest x-rays and vascular structure in CT scans. He is the principal developer of 7 FDA-approved global products.
Derick Sutton
Derick joined Riverain in 2024 and as Chief Financial Officer leads the finance, human resources, IT and manufacturing teams, with a focus on guiding the company’s strategic direction and financial performance. He has built and lead finance teams at growth-stage SaaS and healthcare businesses, including Simplee and SCI Solutions. Derick also worked at Wells Fargo, Bain & Company, and Intuit. He holds an MBA from the University of North Carolina at Chapel Hill and a BA in business economics from UC Riverside.
Riverain Technologies’ solutions are verified, validated, and FDA-cleared. Our technology has been substantiated by peer-reviewed articles, third party studies, and reference accounts. That’s why so many respected healthcare organizations have partnered with Riverain Technologies to bring the power of ClearRead technology with imaging devices, AI platforms and PACS. You can contact these partners directly or work with a Riverain representative for more information.
Our technology is revolutionizing radiology. We’d love to work with you to help create better outcomes for patients everywhere.
